Abstract
Original language | English |
---|---|
Pages (from-to) | e698-e706 |
Journal | Lancet. Haematology |
Volume | 9 |
Issue number | 9 |
DOIs | |
Publication status | Published - 1 Sept 2022 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Lancet. Haematology, Vol. 9, No. 9, 01.09.2022, p. e698-e706.
Research output: Contribution to journal › Review article › Academic › peer-review
TY - JOUR
T1 - Development of an international standard set of outcome measures for patients with venous thromboembolism
T2 - an International Consortium for Health Outcomes Measurement consensus recommendation
AU - Gwozdz, Adam M.
AU - de Jong, Cindy M. M.
AU - Fialho, Luz Sousa
AU - Likitabhorn, Theerawich
AU - Sossi, Frieda
AU - Jaber, Paula Blancarte
AU - Højen, Anette Arbjerg
AU - Arcelus, Juan I.
AU - Auger, William R.
AU - Ay, Cihan
AU - Barco, Stefano
AU - Gazzana, Marcelo B.
AU - Bayley, Julie
AU - Bertoletti, Laurent
AU - Cate-Hoek, Arina ten
AU - Cohen, Alexander T.
AU - Connors, Jean M.
AU - Galanaud, Jean-Philippe
AU - Labropoulos, Nicos
AU - Langlois, Nicole
AU - Meissner, Mark H.
AU - Noble, Simon
AU - Nossent, Esther J.
AU - de León Lovatón, Paula Ponce
AU - Robert-Ebadi, Helia
AU - Rosovsky, Rachel P.
AU - Smolenaars, Noa
AU - Toshner, Mark
AU - Tromeur, C. cile
AU - Wang, Kang-Ling
AU - Westerlund, Eli
AU - de Wit, Kerstin
AU - Black, Stephen A.
AU - Klok, Frederikus A.
N1 - Funding Information: This project was supported from unrestricted grants from Bayer, Boston Scientific, The Dutch Thrombosis Association, Leiden University Medical Center, Leo Pharma, and King's College London. The European Society for Vascular Surgery, the North American Thrombosis Forum, the Swiss Society of Angiology, and the Italian Society of Hemostasis and Thrombosis expressed written support of the project or accepted the project as a formal society's project. JB and NS were the patient representatives of our working group. Funding Information: This project was supported from unrestricted grants from Bayer, Boston Scientific, The Dutch Thrombosis Association, Leiden University Medical Center, Leo Pharma, and King's College London. The European Society for Vascular Surgery, the North American Thrombosis Forum, the Swiss Society of Angiology, and the Italian Society of Hemostasis and Thrombosis expressed written support of the project or accepted the project as a formal society's project. JB and NS were the patient representatives of our working group. Funding Information: AAH reports research grants from The Danish Heart Foundation and The Novo Nordisk Foundation, consulting fees from Bayer and The Bristol-Myers Squibb-Pfizer Alliance, speaker bureaus from Bayer, The Bristol-Myers Squibb-Pfizer Alliance, and Merck Sharp & Dohme, and role as vice chair of special interest group venous thromboembolism of Danish Nurses’ Council. JIA reports honoraria from Sanofi and Rovi for educational activities, and research funding from Sanofi and Bayer AG. WRA reports payment or honoraria from Bayer Pharmaceuticals, support for attending meeting from Bayer Pharmaceuticals, and participation as Clinical Advisor for Janssen. CA received personal fees for lectures and participation in advisory boards from Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, and Sanofi. SB reports unrestricted scientific grants from Bayer, INARI, Boston Scientific, Medtronic, Bard, SANOFI, and Concept Medical; consulting fees from INARI, Bayer, Boston Scientific, and Concept Medical; and travel financial support for attending meetings from Bayer and Daiichi Sankyo. LB reports personal fees and non-financial support from Aspen, personal fees and non-financial support from Bayer, Bristol Myers Squibb-Pfizer, Leo Pharma, and Johnson and Johnson; grants, personal fees and non-financial support from Merck Sharp & Dohme, outside the submitted work. ATC reports grants from Alexion Pharmaceuticals, Bayer Pharma AG, and Bristol Myers Squibb-Pfizer, consulting fees from Alexion Pharmaceuticals, Bayer Pharma AG, and Bristol Myers Squibb-Pfizer, and payments from Alexion Pharmaceuticals, Bayer Pharma AG, and Bristol Myers Squibb-Pfizer, all fees paid to his company. HR-E reports speaker's honoraria from Bayer and Daichi-Sankyo, and support for attending meetings and travel from Bayer. RPR reports consulting fees from Bristol Myers Squibb, Janssen, Inari, Penumbra, Abbott, and research grants paid to her institution from Bristol Myers Squibb and Janssen, all outside the scope of this paper. CT reports honoraria from Riche Bayer, Astra Zeneca, Actelion, and Janssen. K-LW reports honoraria from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer for Continuing Medical Education lectures. SAB reports consulting fees from Boston Scientific, Gore, Becton Dickinson, Cook, Phillips, Vesper, Veryan, Vetex, and Medtronic; honoraria from Boston Scientific, Gore, Becton Dickinson, Cook, Philips, Vesper, Veryan, Vetex, and Medtronic; research grants from Boston Scientific and Medtronic that are paid to his institution; is on the advisory board for Philips, Medtronic, Gore, and Boston Scientific. FAK reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Merck Sharp & Dohme, Leo Pharma, Daiichi-Sankyo, Actelion, The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation, and the Horizon Europe Program, all outside the submitted work and paid to his institution. All other authors declare no competing interests. Publisher Copyright: © 2022 Elsevier Ltd
PY - 2022/9/1
Y1 - 2022/9/1
N2 - The International Consortium for Health Outcomes Measurement assembled an international working group of venous thromboembolism experts and patient representatives to develop a standardised minimum set of outcomes and outcome measurements for integration into clinical practice and potentially research to support clinical decision making and benchmarking of quality of care. 15 core outcomes important to patients and health-care professionals were selected and categorised into four domains: patient-reported outcomes, long term consequences of the disease, disease-specific complications, and treatment-related complications. The outcomes and outcome measures were designed to apply to all patients with venous thromboembolism aged 16 years or older. A measurement tool package was selected for inclusion in the core standard set, with a minimum number of items to be measured at predefined timepoints, which capture all core outcomes. Additional measures can be introduced to the user by a cascade opt-in system that allows for further assessment if required. This set of outcomes and measurement tools will facilitate the implementation of the use of patient-centred outcomes in daily practice.
AB - The International Consortium for Health Outcomes Measurement assembled an international working group of venous thromboembolism experts and patient representatives to develop a standardised minimum set of outcomes and outcome measurements for integration into clinical practice and potentially research to support clinical decision making and benchmarking of quality of care. 15 core outcomes important to patients and health-care professionals were selected and categorised into four domains: patient-reported outcomes, long term consequences of the disease, disease-specific complications, and treatment-related complications. The outcomes and outcome measures were designed to apply to all patients with venous thromboembolism aged 16 years or older. A measurement tool package was selected for inclusion in the core standard set, with a minimum number of items to be measured at predefined timepoints, which capture all core outcomes. Additional measures can be introduced to the user by a cascade opt-in system that allows for further assessment if required. This set of outcomes and measurement tools will facilitate the implementation of the use of patient-centred outcomes in daily practice.
UR - http://www.scopus.com/inward/record.url?scp=85137109916&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/S2352-3026(22)00215-0
DO - https://doi.org/10.1016/S2352-3026(22)00215-0
M3 - Review article
C2 - 36055334
SN - 2352-3026
VL - 9
SP - e698-e706
JO - Lancet. Haematology
JF - Lancet. Haematology
IS - 9
ER -